In This Episode
“The ability to continue driving for another year or two, or to continue working for another year or two, or to continue living–you know, it’s basically living, right? It’s doing the activities of life–is much more meaningful and important than a couple of points on a memory test.”
Phil Gutis reports on the Biogen presentation at CTAD and what it means for people living with an Alzheimer’s diagnosis in the first part of this two-part episode.
(33 minutes)
Show Notes
Related
-
-
Roundup from Clinical Trials on Alzheimer’s Disease (CTAD) Day One: Biogen, Blood Pressure Control
-
Biogen Reports Drug Effective in Slowing Alzheimer’s Disease: ‘A Milestone Achievement’
- Biogen Trial Participant Seeks to Understand Science Behind Alzheimer’s Drug
-
For Alzheimer’s Patient, Hope Renewed Following Biogen Announcement
- The only four currently approved dementia-specific medications: Aricept (donepezil), Razadyne (galantamine) , Exelon (rivastigmine), and Namenda (memantine)
- How did the amyloid hypothesis go from promising to perilous in the search for Alzheimer’s treatments?
-
Resources
For Care Partners
Dementia can last 20+ years.
That's a long time to struggle with trial and error!
If you're ready to step out of overwhelm (and anxiety about the future), click the button below now to schedule your complimentary Dementia Caregiver Strategy call with Christy. (Mobile users, click HERE.)
It's time for you and your person to step into the life you deserve.
Archive
With Host Christy Turner of Dementia Sherpa (Episodes 79-current)
With Host Mike Good of Together in This (Episodes 1-78)
Mike Good founded The Alzheimer’s Podcast in May 2017. Christy appears as a guest in episodes 15, 19, 21, and 23-26. She became the featured expert on the show starting with episode 28 and appears in every episode after, except 56. When Mike decided to follow his bliss, Christy took over the show in January 2019.
Questions? Comments?
If you have questions or comments for Phil (or me), please let us know! We love hearing from you 🙂